Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marianna Maddaloni"'
Autor:
Marianna Maddaloni, Rossella Farra, Barbara Dapas, Fulvia Felluga, Fabio Benedetti, Federico Berti, Sara Drioli, Mattia Vidali, Maja Cemazar, Urska Kamensek, Claudio Brancolini, Erminio Murano, Francesca Maremonti, Mario Grassi, Alice Biasin, Flavio Rizzolio, Enrico Cavarzerani, Bruna Scaggiante, Roberta Bulla, Andrea Balduit, Giuseppe Ricci, Gabriella Zito, Federico Romano, Serena Bonin, Eros Azzalini, Gabriele Baj, Domenico Tierno, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 16, Iss 5, p 664 (2024)
Background: The identification of novel therapeutic strategies for ovarian cancer (OC), the most lethal gynecological neoplasm, is of utmost urgency. Here, we have tested the effectiveness of the compound 2c (4-hydroxy-2,6-bis(4-nitrobenzylidene)cycl
Externí odkaz:
https://doaj.org/article/9cda9d91d298443aa1fd39a5f208d7da
Autor:
Rossella Farra, Matea Maruna, Francesca Perrone, Mario Grassi, Fabio Benedetti, Marianna Maddaloni, Maguie El Boustani, Salvo Parisi, Flavio Rizzolio, Giancarlo Forte, Fabrizio Zanconati, Maja Cemazar, Urska Kamensek, Barbara Dapas, Gabriele Grassi
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 547 (2019)
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as
Externí odkaz:
https://doaj.org/article/3b375c75ea73465e80818a3b526cc03d
Autor:
Gabriele Grassi, Barbara Dapas, Manuel Torralba, Marianna Maddaloni, Mario Grassi, Rossella Farra
Publikováno v:
Current Medicinal Chemistry. 27:7222-7233
Background: Ovary Carcinoma (OC) is the most lethal gynecological neoplasm due to the late diagnoses and to the common development of resistance to platinum-based chemotherapy. Thus, novel therapeutic approaches are urgently required. In this regard,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e6c74036a93c6b9be9e802b5ed859a
https://doi.org/10.2174/0929867327666200713190520
https://doi.org/10.2174/0929867327666200713190520
Autor:
Fabio Benedetti, Gabriele Grassi, Flavio Rizzolio, Rossella Farra, Maja Cemazar, Urska Kamensek, Matea Maruna, Maguie El Boustani, Marianna Maddaloni, Mario Grassi, Salvatore Parisi, Giancarlo Forte, Barbara Dapas, Fabrizio Zanconati, Francesca Perrone
Publikováno v:
Pharmaceutics
Pharmaceutics, Vol 11, Iss 10, p 547 (2019)
Pharmaceutics, Vol 11, Iss 10, p 547 (2019)
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7553a630d18365876c74c4f698b43cd
http://hdl.handle.net/11368/2953008
http://hdl.handle.net/11368/2953008
